Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings ... fatigue (55.6% vs 1.5%), pain (38.9% vs 9.2%), breathing difficulties ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

Spinal cord compression can also occur in sarcoma, myeloma, leukemia ... Nurses should watch for early symptoms (particularly pain), obtain a thorough history, perform a complete physical ...

Better understanding of the complex relationship between mind and body may provide new treatment strategies for chronic pain, ...